Abstract:Advances in genetics, proteomics and chromatography techniques have enabled the successfully generation of a cell-free bacterial translation system composed of highly pure and active components. This system provided an ideal platform for better elucidating the mechanism of each individual step of the prokaryotic protein biosynthesis and the function of the translation factors involved in the process. In doing so, we have discovered that the N-terminal domain or complete deletions of the ribosomal protein L11 reduced the termination efficiency of RF1 on cognate stop codons by four to six folds. The L11 deletions also conferred a two folds decrease in the missense error suggesting the increased nonsense termination accuracy of RF2 by two folds, which would clarified previous in vivo observations. The versatility of the cell-free system has provided the additional possibility to study the effects of class II release factor RF3 mutations in mediating fast dissociation of class I release factors RF1 and RF2 from the post-termination ribosome complexes. The results show a series of mutations within RF3 conferring considerable reduction of the class I release factors recycling rate. These observations together with sequence alignment studies suggest the possible location on RF3 of the class I release factors interaction site. In addition, the utilization of the cell-free system has made it possible to develop a new biotechnological approach for continuous production of polypeptides, based on gel filtration chromatography. The pilot trials have so far resulted in a six fold production increase of the MFTI test peptide compared to the conventional batch method.

Development of Lyophilized Eukaryotic Cell-Free Protein Expression System Based on Leishmania tarentolae

Strategy Exploration for Developing Robust Lyophilized Cell-Free Systems

A novel chemically defined medium for the biotechnological and biomedical exploitation of the cell factory Leishmania tarentolae

Leishmania tarentolae as a platform for the production of vaccines against viral pathogens

Generation and characterization of a Leishmania tarentolae strain for site-directed in vivo biotinylation of recombinant proteins

Development Of A Robust Escherichia Coli-Based Cell-Free Protein Synthesis Application Platform

Construction of an Efficient Escherichia Coli Cell‐free System for in Vitro Expression of Several Kinds of Proteins

Functional Analysis of E. Coli Class II Release Factor RF3 Mutants

Rapid and Scalable Preparation of Bacterial Lysates for Cell-Free Gene Expression

Establishing a Eukaryotic Pichia pastoris Cell-Free Protein Synthesis System

A Cost-Effective Pichia pastoris Cell-Free System Driven by Glycolytic Intermediates Enables the Production of Complex Eukaryotic Proteins

A Low-Cost, Thermostable, Cell-Free Protein Synthesis Platform for On-Demand Production of Conjugate Vaccines

Development of the Low-Temperature Inducible System for Recombinant Protein Production in Escherichia coli Nissle 1917

Establishing a Klebsiella pneumoniae-Based Cell-Free Protein Synthesis System

Development of a full-length human protein production pipeline

Engineering low-temperature expression systems for heterologous production of cold-adapted enzymes

Expression of Novel L-Leucine Dehydrogenase and High-Level Production of L-Tert-Leucine Catalyzed by Engineered Escherichia coli

Development and Comparison of Cell-Free Protein Synthesis Systems Derived from Typical Bacterial Chassis

Efficient Expression in Leishmania tarentolae (LEXSY) of the Receptor-Binding Domain of the SARS-CoV-2 S-Protein and the Acetylcholine-Binding Protein from Lymnaea stagnalis

In Vitro Reconstitution and Analysis of SARS-CoV-2/Host Protein-Protein Interactions

Controllable Autolytic Leaky E. coli Platform for the Recovery of Intracellular Proteins